Humana shares jump 15% as 2027 Medicare Advantage ratings improvement promises up to $4.8bn in bonuses

Humana shares rose 15% on Friday following a substantial improvement in its 2027 Medicare Advantage star ratings. This material is for informational purposes only, and the analysis is based on actuarial science and risk assessment methodologies.

Humana reported that 95% of its Medicare Advantage members will be enrolled in plans rated four stars or higher in 2027, up from 20% in 2026. Evercore ISI analysts estimate this could generate approximately $4.8 billion in bonus payments for Humana in 2028. This performance exceeded J.P. Morgan’s projections of 60% to 70% enrollment in highly rated plans.

From an actuarial perspective, this event highlights the critical importance of star ratings in the US health insurance sector. These ratings are not merely quality metrics but act as fundamental actuarial coefficients that determine government subsidy levels. For Humana, this marks a significant recovery following two difficult cycles. Notably, in October 2025, the company lost a lawsuit challenging the methodology used to calculate its star ratings, which had previously pressured its financial outlook.

However, analysts at Baird note that the impact on profitability will depend on how much of this additional funding Humana reinvests in member benefits versus arrangements with healthcare providers. This is a classic actuarial dilemma regarding operational risk management and capital allocation.

Actuarial Conclusion: The rating shift is an indicator of the effectiveness of the company's actuarial models and quality control systems. When assessing future profitability, it is necessary to account not only for the nominal bonus amount but also for the impact of reinvestment strategies on profit margins.

Source: Beinsure, 2026-10-11. Also reported by: Reuters, J.P. Morgan.